CoChat

The Efficacy and Tolerability of Ezetimibe in Cardiac Transplant Recipients Taking Cyclosporin

The DOI matches its Crossref record; 20 of the 20 references it cites were found in a registry or an index.

Abstract

BACKGROUND: Despite statin treatment, hyperlipidemia remains problematic after cardiac transplantation and is associated with the development of cardiac allograft vasculopathy. The cholesterol absorption inhibitor ezetimibe may offer a viable option for add on therapy; however, questions have been raised regarding the safety of this during concomitant cyclosporin treatment. METHODS: This is the first placebo controlled, randomized double blinded trial assessing the efficacy and tolerability of ezetimibe in cardiac transplant recipients receiving cyclosporin. Sixty-eight cardiac transplant patients were randomized to receive ezetimibe (10 mg) or matching placebo for 6 months in addition to usual treatments. Fasting blood tests were performed at regular time intervals during the study. RESULTS: Fifty-nine patients completed the study. At 6 months, ezetimibe had reduced total cholesterol by 18% (5.4+/-1.1 to 4.4+/-0.7 mmol/L, P<0.001), low-density lipoprotein cholesterol by 26% (3.0+/-1.0 to 2.1+/-0.7 mmol/L, P<0.001), and triglycerides by 13.5% (2.3+/-1.3 to 1.8+/-0.9 mmol/L, P=0.02). Tolerability was excellent with no patients experiencing predefined safety endpoints. An equal number of patients withdrew consent from each arm of the study because of perceived side effects. Specific analysis confirmed ezetimibe had no significant effect on cyclosporin levels. CONCLUSION: We conclude that ezetimibe is both efficacious and tolerable in cardiac transplant recipients taking cyclosporin. It can be safely considered as add on therapy in patients taking statins (or as monotherapy) to further reduce low-density lipoprotein levels, which may in turn reduce the risk of cardiac allograft vasculopathy.

Overview

Integrity signals

Registry

Crossref · 10.1097/tp.0b013e318198d7d0

Cites

20 of 20 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 20 references

Cited by

See all 31

Metadata

Authors
Shaw, S. M., Chaggar, P., Ritchie, J., Shah, M. K. H., Baynes, A. C., O’Neill, N., Fildes, J. E., Yonan, N., & Williams, S. G.
Affiliations
Wythenshawe Hospital (GB)
Corresponding author
Shaw, Steven M.
Venue
Transplantation
Published
2009-03-15
Volume
87
Issue
5
Pages
771-775
ISSN
0041-1337 (ISSN-L)
OpenAlex
W2142988574
Cited by
31
References
20
Citations by year
2026: 1 · 2025: 2 · 2024: 2 · 2022: 1 · 2020: 2 · 2019: 4 · 2016: 3 · 2015: 1 · 2014: 3 · 2013: 3 · 2012: 2
FWCI
3.03
Type
journal article
Language
en
Open access
closed
Locations
  • Transplantation (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion)
Topics
  • Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
  • Health Sciences › Medicine › Surgery › Transplantation: Methods and Outcomes
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Cholesterol and Lipid Metabolism
Keywords
ezetimibe, cyclosporine, heart transplantation, hyperlipidemia, cholesterol absorption inhibitors, LDL cholesterol lowering, triglycerides, drug-drug interactions, cardiac allograft vasculopathy, tolerability
MeSH terms
Ezetimibe, Adult, Aged, Anticholesteremic Agents, Azetidines, Cholesterol, Double-Blind Method, Female, Humans, Immunosuppressive Agents, Lipoproteins, LDL, Male, Middle Aged, Placebos, Safety, Heart Transplantation, Cyclosporine, Hydroxymethylglutaryl-CoA Reductase Inhibitors

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.